Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Heart Vessels. 2021 Dec;36(12):1903-1910. doi: 10.1007/s00380-021-01874-3. Epub 2021 May 22.
The Get-With-The-Guidelines-Heart-Failure (GWTG-HF) score is a risk assessment tool to predict mortality in patients with heart-failure (HF). We aimed to evaluate the GWTG-HF score for risk stratification in HF patients with tricuspid regurgitation undergoing trans-catheter tricuspid valve repair (TTVR). In total, 181 patients who underwent TTVR via edge-to-edge repair (86%) or annuloplasty (14%) were enrolled. Patients were categorized into a low- (≤ 43 points), intermediate- (44-53 points) and high-risk score groups (≥ 54 points). TTVR led to an improvement of TR (p < 0.0001) and NYHA (p < 0.0001). Kaplan-Meier analysis and log-rank test revealed that higher GWTG-HF scores were associated with reduced rates of event-free survival regarding mortality (96% vs 89% vs 73%, respectively, p = 0.001) and hospitalization for heart failure (HHF) (89% vs 86% vs 74%, respectively, p = 0.026). After adjusting for important variables like renal function, left ventricular ejection fraction and mitral regurgitation, the GWTG-HF score remained an independent predictor of the composite endpoint of HHF or mortality (hazard ratio 1.04 per 1-point increase, p = 0.029). Other remaining predictors were renal function and mitral regurgitation. The GWTG-HF score used as a risk stratification tool of mortality and HHF maintains its prognostic value in a HF population with severe TR undergoing TTVR.
指南指导下的心衰(GWTG-HF)评分是一种预测心衰(HF)患者死亡率的风险评估工具。我们旨在评估 GWTG-HF 评分在心衰伴三尖瓣反流行经导管三尖瓣修复术(TTVR)患者中的风险分层作用。共有 181 例患者接受了缘对缘修复(86%)或瓣环成形术(14%)的 TTVR。患者被分为低危(≤43 分)、中危(44-53 分)和高危评分组(≥54 分)。TTVR 导致 TR(p<0.0001)和 NYHA(p<0.0001)改善。Kaplan-Meier 分析和对数秩检验显示,较高的 GWTG-HF 评分与死亡率(分别为 96%、89%和 73%,p=0.001)和心衰住院(HHF)(分别为 89%、86%和 74%,p=0.026)的无事件生存率降低相关。在调整肾功能、左心室射血分数和二尖瓣反流等重要变量后,GWTG-HF 评分仍然是 HHF 或死亡率复合终点的独立预测因素(每增加 1 分,风险比为 1.04,p=0.029)。其他剩余的预测因素是肾功能和二尖瓣反流。GWTG-HF 评分作为死亡率和 HHF 的风险分层工具,在心衰伴严重 TR 行经 TTVR 的患者中保持其预后价值。